Business Wire

CO-LIQID-INC.

22.6.2022 17:32:06 CEST | Business Wire | Press release

Share
Case Study: Durham University Deploys Liqid Composable Infrastructure to Study Universe’s 14 Billion-Year History with Adaptive, More Sustainable Infrastructure

LIQID Inc., one of the world’s leading software companies delivering data center composability, announced today a new case study with Durham University in Durham, England, describing its deployment of Liqid composable disaggregated infrastructure (CDI) software. Durham University is home to the COSmology MAchine (COSMA) operated by the Institute for Computational Cosmology (ICC) and is a national supercomputing facility that is part of the UK’s Distributed Research utilizing Advanced Computing (DiRAC) system. Liqid Matrix™ CDI software is part of a system used to study the origins of the universe, composing disaggregated GPUs in a tight footprint designed for a more sustainable digital architecture. With the ability to grow as resources are needed, the Liqid system will help researchers in the UK and around the world unlock the mysteries of the 14 billion-year history of the cosmos with far greater speed and efficiency than traditional data center systems.

“We are honored to work with institutions like Durham University and COSMA researchers to provide the resources to better explore the most profound questions in science,” said Sumit Puri, CEO & Cofounder, Liqid. “By providing the kind of software-defined data performance and architectural flexibility for powerful GPU, Liqid is enabling research breakthroughs that would have been impossible with traditional, static data center architectures so scientists can focus on results instead of waiting for resources and performance to become available.”

Liqid Matrix CDI Delivers Big Bang for Cosmologists with Adaptive, Efficient Architecture

“Durham University is using cutting-edge CDI to accelerate research, improve resource utilization, and reduce the university’s carbon footprint,” said Alistair Basden, technical manager for the DiRAC Memory Intensive Service at Durham University, who was interviewed for the case study entitled Durham University’s Institute for Computational Cosmology Accelerates Results with Composability from Liqid .

The COSMA memory-intensive system is designed specifically to support the largest cosmological simulations, most notably running simulations starting with the Big Bang and propagating through the entire history of the universe. Each simulation of dark matter, dark energy, black holes, galaxies and other structures in the universe often takes months to run, followed by long periods of data analysis.

While all of the applications deployed by DiRAC are memory intensive, valuable GPU resources are required for some of its most challenging simulations and analysis. Durham University chose Liqid Matrix software-based composable system in order to be able to share and scale GPUs in the exact amounts required for any given workload. Once the workload has been completed, GPU resources can be redistributed through Liqid Matrix software for use by other applications.

“It would be wasteful for us to populate all our nodes with GPUs,” Basden said in an interview for the case study. “Instead, we have some fat compute nodes and a login node, and we’re able to move GPUs between those systems. Composing our GPUs gives us flexibility with a smaller number of GPUs. We can individually populate the servers with one or more GPUs as required at the click of a button.”

Durham University IT is also deploying Liqid Matrix-based systems as an element of its overall strategy for a more sustainable IT ecosystem. Software-based composability enables users to do more with less, increasing efficiency and curtailing the need for physical space to store the hardware while providing significant reductions in cooling and water requirements.

“Rather than populating all our servers with GPUs, we can compose the resources we need to each server. That reduces our carbon footprint,” said Basden.

To learn more about Liqid’s academic deployments, review Liqid’s case study outlining the company’s work with the University of Illinois at Chicago’s Electronic Visualization Laboratory . Schedule an appointment with an expert on solutions based on Liqid Matrix ™ CDI software-based and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.

About Liqid Inc.

Liqid’s composable infrastructure software platform, Liqid Matrix ™, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT professionals can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.

Social Media:

https://www.facebook.com/WeAreLiqid/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye